Ping-Chih Hsu

27PUBLICATIONS
53CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersIntensive care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jun 29, 2026
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.

|Feb 13, 2026
Flavones and Aminoflavones Increase the Cytotoxicity of NK Cells in Human Non-Small Cell Lung Cancer.

Ping-Chih Hsu, Chih-Cheng Chien, Yang-Je Cheng

|Jun 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim

|May 25, 2024
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.

Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang

|Jan 27, 2024
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.

Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang

|Jan 22, 2024
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.

Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang

Pageof 5

Frequent Collaborators

11 joint publications

Scott Chih-Hsi Kuo

8 joint publications

Cheng-Ta Yang

6 joint publications

Li-Chung Chiu

3 joint publications

Yueh-Fu Fang